Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease

Study Questions:

What is the prognostic impact of fibroblast growth factor (FGF)-23 in identifying patients with stable ischemic heart disease (SIHD) at high risk of cardiovascular events, and does FGF-23 identify patients who derive greater clinical benefit from angiotensin-converting enzyme (ACE) inhibitor therapy?